Zobrazeno 1 - 10
of 42
pro vyhledávání: ''
Autor:
Yasunori Ueda, Noriko Fukuhara, Shinya Rai, Kenichi Ishizawa, Tomohisa Saito, Koji Izutsu, Yasuhito Terui, Hirohiko Shibayama, Kazuhito Yamamoto, Hideki Goto, Motoko Yamaguchi, Takayuki Ishikawa, Atsuko Kawasaki, Junya Kuroda, Youko Suehiro, Kyoya Kumagai, Ken Ohmine, Jun Takizawa, Misato Hashizume, Nobuhiro Kanemura, Koji Kato
Publikováno v:
Cancer Science
Polatuzumab vedotin (pola) is a CD79b‐targeted antibody‐drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open‐label, single‐arm study of pola 1.8 mg/kg, bendamustine 90 mg/m2, rituximab 37
Autor:
Natalie Andrews Wright, Prisni Rath, Trevor J. Pugh, Glenwood D. Goss, Gemma N Jones, Harmanjatinder S. Sekhon, Natalia Lukashchuk, Kayla Marsh, Bryan Lo, Paola Marco-Casanova, Laurence Bernard, William J. Howat, Dax Torti, Jonathon Torchia, Marc Duciaume, Alberto Leon, Darren Hodgson, Stanley E. Lazic, Johanne I Weberpals, Doreen Whelan, Alexander Fortuna, Martine P. Roudier
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 9, Pp 3045-3058 (2021)
Cancer Medicine, Vol 10, Iss 9, Pp 3045-3058 (2021)
Background In high grade serous ovarian cancer (HGSOC), there is a spectrum of sensitivity to first line platinum‐based chemotherapy. This study molecularly characterizes HGSOC patients from two distinct groups of chemotherapy responders (good vs.
Autor:
Tom Wei-Wu Chen, Herbert H. Loong, Sze Huey Tan, Alex K.C. Leung, Richard Quek, Chih Chi Chang, Angela Pang, Myo Myint Maw, Takeshi Hirose, Makoto Endo, Akira Kawai, Mark E. Puhaindran, Virote Sriuranpong, Siyamol Mingmalairak, Mohamad Farid, Jeffrey C.H. Chan, Wei Lin Goh, Roger K.C. Ngan
Publikováno v:
Cancer Science
Angiosarcoma (AS) is a rare disease with a dismal prognosis. The treatment landscape and prognostic factors for advanced AS, including locally advanced, unresectable, and metastatic disease remain elusive. The Asian Sarcoma Consortium is an internati
Autor:
Nazli Dizman, Bernadett Szabados, Sumanta K. Pal, Frede Donskov, Toni K. Choueiri, Guillermo Velasco, Benoit Beuselinck, Chun Loo Gan, Daniel Y.C. Heng, Aly-Khan A. Lalani, Ulka N. Vaishampayan, J. Connor Wells, Aaron R. Hansen, Nityam Rathi, Georg A. Bjarnason, Ben Tran, Flora Yan, Shaan Dudani, Jae-Lyun Lee, Mathushan Subasri
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
Gan, C L, Dudani, S, Wells, J C, Donskov, F, Pal, S K, Dizman, N, Rathi, N, Beuselinck, B, Yan, F, Lalani, A K A, Hansen, A, Szabados, B, de Velasco, G, Tran, B, Lee, J L, Vaishampayan, U N, Bjarnason, G A, Subasri, M, Choueiri, T K & Heng, D Y C 2021, ' Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium ', Cancer Medicine, vol. 10, no. 4, pp. 1212-1221 . https://doi.org/10.1002/cam4.3717
Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
Gan, C L, Dudani, S, Wells, J C, Donskov, F, Pal, S K, Dizman, N, Rathi, N, Beuselinck, B, Yan, F, Lalani, A K A, Hansen, A, Szabados, B, de Velasco, G, Tran, B, Lee, J L, Vaishampayan, U N, Bjarnason, G A, Subasri, M, Choueiri, T K & Heng, D Y C 2021, ' Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium ', Cancer Medicine, vol. 10, no. 4, pp. 1212-1221 . https://doi.org/10.1002/cam4.3717
Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. Methods Patients with mRCC trea
Autor:
Takeru Wakatsuki, Mariko Ogura, Keisho Chin, Hiroki Osumi, Daisaku Kamiimabeppu, Izuma Nakayama, Daisuke Takahari, Taro Sato, Akira Ooki, Eiji Shinozaki, Kensei Yamaguchi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 2, Pp 615-625 (2021)
Cancer Medicine, Vol 10, Iss 2, Pp 615-625 (2021)
Background Three vascular endothelial growth factor (VEGF) inhibitors, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second‐line chemotherapy. The
Autor:
Kazuhiko Yamada, Yoichi Nakamura, Sakiko Otani, Kazuma Kishi, Takeharu Yamanaka, Hiroshi Tanaka, Haruhiro Saito, Kaoru Kubota, Tsuneo Shimokawa, Yuichi Takiguchi, Hiroaki Okamoto, Toshihiro Misumi, Terufumi Kato, Yukio Hosomi, Daijiro Harada, Takashi Kasai
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 2, Pp 626-633 (2021)
Cancer Medicine, Vol 10, Iss 2, Pp 626-633 (2021)
Cisplatin‐based chemoradiotherapy is considered standard treatment for unresectable locally advanced non‐small‐cell lung cancer (LA‐NSCLC). This study examined two regimens of chemotherapy in concurrent chemoradiation. Eligible patients with
Publikováno v:
Cancer Medicine
Background Hypercalcemia of malignancy (HCM) is a serious metabolic complication, and the highest rates are in multiple myeloma (MM). The cause of hypercalcemia in newly diagnosed multiple myeloma (NDMM) remains unknown. We sought to evaluate the pro
Autor:
Hiroshi Koike, Hiroshi Urakawa, Kunihiro Ikuta, Kan Ito, Yuichi Ando, Tomohisa Sakai, Yoshihiro Nishida, Ryo Emoto, Shigeyuki Matsui, Shunsuke Hamada
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
Low‐dose methotrexate (MTX) plus vinblastine (VBL) chemotherapy is an effective treatment for desmoid‐type fibromatosis (DF). However, previous reports have described a weekly regimen, with no reports available on a biweekly one. The aim of this
Autor:
Ghassan K. Abou-Alfa, Eileen M. O'Reilly, Jinru Shia, Richard K. G. Do, Jennifer Ma, Joanne F. Chou, Marinela Capanu, Imane El Dika, Anna D. Hrabovsky, James J. Harding, Michele Ly, Brittanie M Millang
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 20, Pp 7453-7459 (2020)
Cancer Medicine, Vol 9, Iss 20, Pp 7453-7459 (2020)
Background Patients with advanced hepatocellular carcinoma (HCC) who received second line sorafenib plus doxorubicin following disease progression on sorafenib were shown retrospectively to have improved progression free survival (PFS) and overall su
Autor:
Helen Guo, Steven Habbous, Jaclyn Beca, Wei Fang Dai, Kelvin K. W. Chan, Wanrudee Isaranuwatchai, Matthew C. Cheung
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 19, Pp 7072-7082 (2020)
Cancer Medicine, Vol 9, Iss 19, Pp 7072-7082 (2020)
Introduction For patients with diffuse large B‐cell lymphoma (DLBCL), standard‐care is rituximab administered with CHOP or CHOP‐like chemotherapy (R‐CHOP). However, the effectiveness and safety of R‐CHOP among DLBCL patients with human immu